In contrast, a ‘hot” MYCN-NA tumor without targetable mutation may be better treated with a combination of chemotherapy and an immune checkpoint inhibitor or TGF-β inhibitor to prevent immune escape. This evidence concerns the gene TGFB1 and neoplasm.